PCN236 COST-EFFECTIVENESS OF LENALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN THE CHINESE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA BUT INELIGIBLE FOR STEM CELL TRANSPLANT THERAPY
May 1, 2019, 00:00 AM
10.1016/j.jval.2019.04.357
https://www.valueinhealthjournal.com/article/S1098-3015(19)30549-2/fulltext
Section Title :
Section Order :
10008
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30549-2&doi=10.1016/j.jval.2019.04.357